Literature DB >> 25291651

Dextran hypersensitivity.

A W Richter1, H I Hedin.   

Abstract

Dextran, a common plasma substitute, sometimes induces life-threatening hypersensitivity reactions. In this article Wolfgang Richter and Harriet Hedin discuss recent evidence that these Type III anaphylactic reactions, caused by natural antibodies, can be abolished by pretreatment o f patients with monovalent hapten dextran.
Copyright © 1982. Published by Elsevier B.V.

Entities:  

Year:  1982        PMID： 25291651     DOI： 10.1016/0167-5699(82)90073-1

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  6 in total

Review 1.  Anaphylactoid reactions to intravenous solutions used for volume substitution.

Authors:  J Ring
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

2.  Effect of hypervolaemic haemodilution of regional cerebral blood flow in patients with acute ischaemic stroke: a controlled study with hydroxyethylstarch.

Authors:  A Hartmann; Y Tsuda; H Lagrèze
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

Review 3.  The use of plasma substitutes with special attention to their side effects.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

4.  Fluid therapy in shock.

Authors:  G Arturson; L Thorén
Journal:  World J Surg       Date:  1983-09       Impact factor: 3.352

5.  Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.

Authors:  Birgit Ehlken; Lennart Nathell; Annegret Gohlke; Derya Bocuk; Massoud Toussi; Stefan Wohlfeil
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

6.  Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).

Authors:  Susann Neiser; Taija S Koskenkorva; Katrin Schwarz; Maria Wilhelm; Susanna Burckhardt
Journal:  Int J Mol Sci       Date:  2016-07-21       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.